JPRN-UMIN000017861已完成未知
assessment in patients with Type 2 diabetes mellitus in addition to cOronary artery disease after Percutaneous coronary intervention with regard to Sitagliptin-induced COronary plaque REgression (TOP-SCORE) - TOP-SCORE study
Department of Cardiology, Fukuoka University School of Medicine0 个研究点目标入组 60 人开始时间: 2015年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
The addition of sitagliptin to statins did not cause coronary plaque regression in Type 2 diabetes mellitus with coronary artery disease.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) type 1 diabetes mellitus (2) patients who had experienced ketosis, diabetic coma and/or pre-coma within six months prior to providing consent (3) moderate to severe heart failure (New York Heart Association class 3 or 4, left ventricular ejection fraction <40%) (4) severe valvular heart disease (5) renal dysfunction (creatinine blood level of over 1.5 mg/dL in men and over 1.3 mg/dL in women) (6) familial hypercholesterolemia (7) contraindication to antiplatelet agent(8) history of chemical sensitivity to DPP4-I (9) pregnancy or lactation (10) severe infection, trauma or recent surgery
研究者
相似试验
已完成
3 期
Fenofibrate and Metformin Fixed Combination vs Metformin - FAME METFODyslipidemia/Glucose Metabolism DisorderNCT00362323Solvay Pharmaceuticals482
尚未招募
不适用
The effect of SGLT2 inhibitor on diabetic cardiac autonomic neuropathydiabetes mellitusJPRN-UMIN000033541Sakakibara Heart Institute200
招募中
不适用
Effects of a SGLT2 Inhibitor in type 2 Diabetes Mellitustype 2 Diabetes MellitusJPRN-UMIN000017461ephrology, endocrinology and vascular medicine at Tohoku University Hospital60
已完成
4 期
Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2Myocardial FibrosisMyocardial InflammationType 2 Diabetes MellitusNCT03782259University of Washington62
招募中
不适用
sefulness of sitagliptin for type 2 diabetes pacientsJPRN-UMIN000005769Jikei University School of Medicine, Division of Diabetes, Metabolism and Endocrinology Department of Internal Medicine300